Last reviewed · How we verify
HYML-122; cytarabine
inhibits DNA polymerase
inhibits DNA polymerase Used for Acute myeloid leukemia.
At a glance
| Generic name | HYML-122; cytarabine |
|---|---|
| Sponsor | Tarapeutics Science Inc. |
| Drug class | nucleoside analog |
| Target | DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cytarabine is a nucleoside analog that inhibits DNA polymerase, thereby preventing DNA replication and cell division.
Approved indications
- Acute myeloid leukemia
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HYML-122; cytarabine CI brief — competitive landscape report
- HYML-122; cytarabine updates RSS · CI watch RSS
- Tarapeutics Science Inc. portfolio CI